![](https://t-therapeutics.com/wp-content/uploads/2024/06/David_Hung.jpg)
Industry veteran, founder of Medivation and serial entrepreneur joins T-Therapeutics to support development of the company’s pipeline of TCR-based immuno-oncology drugs 12 June 2024; Cambridge, England – T-Therapeutics, a biotechnology company developing next-generation soluble TCR therapeutics targeting cancer and autoimmune indications, today announces...
Read More